Updated estimates of excess total mortality in Italy during the circulation of the BA.2 and BA.4-5 Omicron variants: April-July 2022.


Journal

La Medicina del lavoro
ISSN: 0025-7818
Titre abrégé: Med Lav
Pays: Italy
ID NLM: 0401176

Informations de publication

Date de publication:
24 Oct 2022
Historique:
received: 17 10 2022
accepted: 17 10 2022
entrez: 25 10 2022
pubmed: 26 10 2022
medline: 27 10 2022
Statut: epublish

Résumé

The impact of new lineages and sub-lineages of Omicron on total and excess mortality is largely unknown. This study aims to provide estimates of excess mortality during the circulation of the Omicron variant in Italy updated to July 2022. Over-dispersed Poisson regression models, fitted separately for men and women, on 2011-2019 mortality data were used to estimate the expected number of deaths during the Covid-19 pandemic. The excess deaths were then obtained by the difference between observed and expected deaths and computed at all ages and at working ages (25-64 years). Between April and June 2022, we estimated 9,631 excess deaths (+6.3%) at all ages (4,400 in April, 3,369 in May, 1,862 in June) and 12,090 in July 2022 (+23.4%). At working ages, the excess was 763 (+4.9%) in April-June 2022 and 679 (+13.0%) in July 2022. Excess total mortality persisted during the circulation of different lineages and sub-lineages of the Omicron variant in Italy. This excess was not limited to the elderly population but involved also working age individuals, though the absolute number of deaths was small. The substantial excess found in July 2022 is, however, largely attributable to high temperatures. At the end of the year, this may translate into 30 to 35,000 excess deaths, i.e. over 5% excess mortality. This reversed the long-term trend toward increasing life expectancy, with the relative implications in social security and retirement schemes.

Sections du résumé

BACKGROUND BACKGROUND
The impact of new lineages and sub-lineages of Omicron on total and excess mortality is largely unknown. This study aims to provide estimates of excess mortality during the circulation of the Omicron variant in Italy updated to July 2022.
METHODS METHODS
Over-dispersed Poisson regression models, fitted separately for men and women, on 2011-2019 mortality data were used to estimate the expected number of deaths during the Covid-19 pandemic. The excess deaths were then obtained by the difference between observed and expected deaths and computed at all ages and at working ages (25-64 years).
RESULTS RESULTS
Between April and June 2022, we estimated 9,631 excess deaths (+6.3%) at all ages (4,400 in April, 3,369 in May, 1,862 in June) and 12,090 in July 2022 (+23.4%). At working ages, the excess was 763 (+4.9%) in April-June 2022 and 679 (+13.0%) in July 2022.
CONCLUSIONS CONCLUSIONS
Excess total mortality persisted during the circulation of different lineages and sub-lineages of the Omicron variant in Italy. This excess was not limited to the elderly population but involved also working age individuals, though the absolute number of deaths was small. The substantial excess found in July 2022 is, however, largely attributable to high temperatures. At the end of the year, this may translate into 30 to 35,000 excess deaths, i.e. over 5% excess mortality. This reversed the long-term trend toward increasing life expectancy, with the relative implications in social security and retirement schemes.

Identifiants

pubmed: 36282028
doi: 10.23749/mdl.v113i5.13825
pmc: PMC9632669
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2022046

Références

Med Lav. 2022 Apr 26;113(2):e2022021
pubmed: 35481574
JAMA. 2021 Apr 2;:
pubmed: 33797550
Med Lav. 2020 Oct 31;111(5):351-353
pubmed: 33124605
Int J Epidemiol. 2022 Feb 18;51(1):63-74
pubmed: 34564730
Nat Immunol. 2022 Feb;23(2):194-202
pubmed: 35105985
BMJ. 2022 Apr 6;377:e069590
pubmed: 35387772
Nat Rev Immunol. 2022 May;22(5):267-269
pubmed: 35414124
Eur Heart J. 2022 Mar 14;43(11):1157-1172
pubmed: 35176758
Med Lav. 2022 Jun 28;113(3):e2022030
pubmed: 35766642
Lung. 2022 Oct;200(5):573-577
pubmed: 36114845
Sci Rep. 2021 Nov 2;11(1):21526
pubmed: 34728729
Nat Med. 2022 Oct;28(10):2117-2123
pubmed: 36064600
Nat Med. 2022 Mar;28(3):583-590
pubmed: 35132265

Auteurs

Gianfranco Alicandro (G)

Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy 2Cystic Fibrosis Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. gianfranco.alicandro@istat.it.

Alberto Giovanni Gerli (AG)

Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. alberto.gerli@unimi.it.

Giuseppe Remuzzi (G)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy. giuseppe.remuzzi@marionegri.it.

Stefano Centanni (S)

Respiratory Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, Università degli Studi di Milano, Milan, Italy. stefano.centanni@unimi.it.

Carlo La Vecchia (C)

Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy. carlo.lavecchia@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH